Roquefort Shareholders Back AO-252 Deal and £8.5m Fundraise Ahead of AIM Switch

The latest update is out from Roquefort Investments PLC ( (GB:ROQ) ).

Roquefort Therapeutics shareholders have approved all resolutions at a general meeting, clearing the way for the acquisition of an exclusive worldwide licence to AO-252 from Coiled Therapeutics Inc., a clinical-stage oncology spin-out of A2A Pharma. The company is simultaneously completing an £8.5 million fundraising, share reorganisation and Rule 9 waiver, while its board and incoming executives, including proposed executive chairman Dr Sotirios Stergiopoulos and proposed CEO Sridhar Vempati, are subscribing for shares.

The company will cancel its Main Market listing, with today marking the last day of trading in its existing ordinary shares, and will be admitted to trading on AIM at 8:00 a.m. on 27 March 2026 under its new name, Coiled Therapeutics plc, with 425,856,539 new ordinary shares in issue. This transition, combined with the AO-252 licence and fresh capital, reshapes the group as an AIM-listed oncology specialist with enhanced funding and leadership alignment, potentially improving its flexibility for future clinical and corporate development initiatives.

The most recent analyst rating on (GB:ROQ) stock is a Sell with a £1.00 price target. To see the full list of analyst forecasts on Roquefort Investments PLC stock, see the GB:ROQ Stock Forecast page.

Spark’s Take on ROQ Stock

According to Spark, TipRanks’ AI Analyst, ROQ is a Neutral.

The score is primarily held back by weak financial fundamentals (pre-commercial revenue volatility, ongoing losses and cash burn). Technical indicators also point to a sustained downtrend. Low leverage on the balance sheet provides some support, but the negative P/E and lack of dividend yield limit valuation appeal.

To see Spark’s full report on ROQ stock, click here.

More about Roquefort Investments PLC

Roquefort Therapeutics plc, which will be renamed Coiled Therapeutics plc, operates in the biotechnology and oncology sector, focusing on the development of novel small molecule cancer therapies. Through its association with Coiled Therapeutics Inc. and Coiled USA, the company is targeting brain-penetrant inhibitors such as AO-252 to address cancers that have progressed on existing treatments, positioning itself in early-stage clinical oncology innovation.

Average Trading Volume: 955,481

Technical Sentiment Signal: Sell

Current Market Cap: £1.64M

Learn more about ROQ stock on TipRanks’ Stock Analysis page.